⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5607861 | 0.97 | GRM1 (0.42) | — | |
| SCHEMBL1732675 | 0.97 | GRM1 (0.42) | — | |
| SCHEMBL5607460 | 0.94 | GRM1 (0.41) | — | |
| SCHEMBL5607548 | 0.83 | PKM (0.43) | — | |
| SCHEMBL5607856 | 0.83 | PKM (0.43) | — | |
| SCHEMBL1733355 | 0.83 | PKM (0.48) | — | |
| SCHEMBL541485 | 0.83 | GRM1 (0.34) | — | |
| SCHEMBL9142496 | 0.82 | GRM1 (0.50) | — | |
| SCHEMBL1648486 | 0.82 | GRM1 (0.50) | — | |
| SCHEMBL13089716 | 0.79 | GRM1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT (FR) | 2026-01-22 | — | — | US | disclosed |
| EP-4371987-B9 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4646197-A2 | ORGANIC COMPOUNDS AS NLRP3 INHIBITORS | Kodiak Sciences Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| WO-2025224262-A1 | COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR | MONTE ROSA THERAPEUTICS AG (CH) | 2025-10-30 | — | — | WO | disclosed |
| EP-4371987-B1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4608816-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | Monte Rosa Therapeutics AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-21 | — | — | US | disclosed |
| WO-2025149545-A1 | HETEROARYLPHENYL ETHER DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2025-07-17 | — | — | WO | disclosed |
| US-20250214942-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-07-03 | — | — | US | disclosed |
| EP-4558500-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-05-28 | — | — | EP | disclosed |
| US-9447025-B2 | Bicyclic analgesic compounds | KALYRA PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447026-B2 | Bicyclic analgesic compounds | KALYRA PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447026-B2 | Bicyclic analgesic compounds | KALYRA PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160016892-A1 | BICYCLIC ANALGESIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016892-A1 | BICYCLIC ANALGESIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016892-A1 | BICYCLIC ANALGESIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| WO-2014149819-A1 | BICYCLIC ANALGESIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275245-A1 | BICYCLIC ANALGESIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275245-A1 | BICYCLIC ANALGESIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275245-A1 | BICYCLIC ANALGESIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |